Evidence map›Paper›PMID 34820133›Full record

ArticleCanadian journal of kidney health and disease2021

A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol.

Anshika Jain, Ryan Huang, Jasmine Lee, Natasha Jawa, Yong Jin Lim, Mike Guron, Sharon Abish, Paul C Boutros, Michael Brudno, Bruce Carleton and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 2 countries.

Anshika JainChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
Ryan HuangChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
Jasmine LeeChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.
Natasha JawaDivision of Nephrology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Yong Jin LimDepartment of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Mike GuronDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.
Sharon AbishDivision of Hematology and Oncology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada.
Paul C BoutrosComputational Biology Program, Ontario Institute for Cancer Research, Toronto, Canada.
Michael BrudnoDepartment of Computer Science, University of Toronto, ON, Canada.
Bruce CarletonDepartment of Pediatrics, The University of British Columbia, Vancouver, Canada.
Geoffrey D E CuvelierCancerCare Manitoba, University of Manitoba, Winnipeg, Canada.
Lakshman GunaratnamDivision of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Cheryl HoMedical Oncology, BC Cancer, The University of British Columbia, Vancouver, Canada.
Khosrow AdeliMolecular Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
Sara KuruvillaDivision of Medical Oncology, Department of Oncology, Western University, London, ON, Canada.
Giles LajoieDepartment of Biochemistry, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Paul C NathanDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Shahrad Rod RassekhDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.
Michael RiederDepartment of Pediatrics, Western University, London, ON, Canada.
Sushrut S WaikarSection of Nephrology, Boston University School of Medicine, MA, USA.
Stephen A WelchDivision of Medical Oncology, Department of Oncology, Western University, London, ON, Canada.
Matthew A WeirDivision of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Eric WinquistDivision of Medical Oncology, Department of Oncology, Western University, London, ON, Canada.
David S WishartDepartment of Biochemistry, University of Alberta, Edmonton, Canada.
Alexandra P ZorziDivision of Hematology/Oncology, Department of Pediatrics, Children's Hospital, Western University, London, ON, Canada.
Tom Blydt-HansenDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.
Michael ZappitelliChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-9977-0536
Bradley UrquhartDepartment of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Western University · CAHospital for Sick Children · CAUniversity of British Columbia · CAUniversity of Toronto · CABoston University · USCancerCare Manitoba · CAMontreal Children's Hospital · CAOntario Institute for Cancer Research · CAUniversity Health Network · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor for chronic kidney disease and mortality. AKI diagnosis relies on biomarkers which are only measurable after kidney damage has occurred and functional impairment is apparent; this prevents timely AKI diagnosis and treatment. Metabolomics seeks to identify metabolite patterns involved in cell tissue metabolism related to disease or patient factors. The A Canadian study of Cisplatin mEtabolomics and NephroToxicity (ACCENT) team was established to harness the power of metabolomics to identify novel biomarkers that predict risk and discriminate for presence of cisplatin nephrotoxicity, so that early intervention strategies to mitigate onset and severity of AKI can be implemented.

objectiveDescribe the design and methods of the ACCENT study which aims to identify and validate metabolomic profiles in urine and serum associated with risk for cisplatin-mediated nephrotoxicity in children and adults.

designObservational prospective cohort study.

settingSix Canadian oncology centers (3 pediatric, 1 adult and 2 both). PATIENTS: Three hundred adults and 300 children planned to receive cisplatin therapy. MEASUREMENTS: During two cisplatin infusion cycles, serum and urine will be measured for creatinine and electrolytes to ascertain AKI. Many patient and disease variables will be collected prospectively at baseline and throughout therapy. Metabolomic analyses of serum and urine will be done using mass spectrometry. An untargeted metabolomics approach will be used to analyze serum and urine samples before and after cisplatin infusions to identify candidate biomarkers of cisplatin AKI. Candidate metabolites will be validated using an independent cohort.

methodsPatients will be recruited before their first cycle of cisplatin. Blood and urine will be collected at specified time points before and after cisplatin during the first infusion and an infusion later during cancer treatment. The primary outcome is AKI, defined using a traditional serum creatinine-based definition and an electrolyte abnormality-based definition. Chart review 3 months after cisplatin therapy end will be conducted to document kidney health and survival. LIMITATIONS: It may not be possible to adjust for all measured and unmeasured confounders when evaluating prediction of AKI using metabolite profiles. Collection of data across multiple sites will be a challenge.

conclusionsACCENT is the largest study of children and adults treated with cisplatin and aims to reimagine the current model for AKI diagnoses using metabolomics. The identification of biomarkers predicting and detecting AKI in children and adults treated with cisplatin can greatly inform future clinical investigations and practices.

Indexed as

acute kidney injurycisplatin nephrotoxicitycohort studymetabolomicspediatrics

Identifiers

PMID34820133
PMCPMC8606978
OpenAlexW3212852675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.